NeoGenomics Posts 11% Revenue Growth on NGS Expansion
Event summary
- NeoGenomics reported $202M in Q2 2026 revenue, up 11% YoY, with clinical revenue growing 14% on 26% NGS growth.
- Adjusted EBITDA increased 36% to $14M, while GAAP net income was $2M including a $11M debt extinguishment gain.
- Completed $316M private offering of convertible senior notes due 2032 and repurchased $276M in existing debt.
- Submitted third RaDaR ST evidence submission to MolDx for Medicare reimbursement pending approval.
The big picture
NeoGenomics' Q2 results reflect ongoing transition toward higher-margin next-generation sequencing (NGS) diagnostics. The company's strategic focus on reimbursement expansion through MolDx submissions and debt restructuring positions it for sustained profitability in the competitive oncology testing market.
What we're watching
- Reimbursement Momentum
- Whether the pending MolDx approval for RaDaR ST will expand Medicare coverage and drive further clinical volume growth.
- Debt Management
- How NeoGenomics' $316M convertible note offering impacts its capital structure and financial flexibility.
- NGS Shift
- The pace at which NGS testing adoption accelerates as a percentage of total revenue, given its 26% growth rate.
Related topics